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The psychometric properties of 4 paradigms adapted from 
the social neuroscience literature were evaluated to deter-
mine their suitability for use in clinical trials of schizo-
phrenia. This 2-site study (University of California, Los 
Angeles and University of North Carolina) included 173 
clinically stable schizophrenia outpatients and 88 healthy 
controls. The social cognition battery was administered 
twice to the schizophrenia group (baseline, 4-week retest) 
and once to the control group. The 4 paradigms included 2 
that assess perception of nonverbal social and action cues 
(basic biological motion and emotion in biological motion) 
and 2 that involve higher level inferences about self and oth-
ers’ mental states (self-referential memory and empathic 
accuracy). Each paradigm was evaluated on (1) patient vs 
healthy control group differences, (2) test-retest reliability, 
(3) utility as a repeated measure, and (4) tolerability. Of the 
4 paradigms, empathic accuracy demonstrated the strongest 
characteristics, including large between-group differences, 
adequate test-retest reliability (.72), negligible practice 
effects, and good tolerability ratings. The other paradigms 
showed weaker psychometric characteristics in their cur-
rent forms. These findings highlight challenges in adapting 
social neuroscience paradigms for use in clinical trials.
Key words: social neuroscience/schizophrenia/ 
psychometrics
Introduction
Studies of social cognitive processes in schizophrenia 
have yielded important new findings concerning their 
relationship with community functioning,1–6 formation 
of psychotic symptoms,7–10 and aberrant brain function-
ing.11–13 For these reasons, social cognitive impairments 
are increasingly regarded as promising targets for phar-
macological and behavioral interventions.14 However, 
a prominent obstacle for treatment development in this 
area is the absence of standardized measures of specific 
subprocesses with established reliability and validity that 
are suitable for clinical trials.
Social cognition is often assessed in schizophrenia 
using measures that were developed several decades ago. 
Examples include identifying an emotion depicted in a still 
photograph or reading a vignette depicting a social interac-
tion.15–18 Not surprisingly, many of the tests were borrowed 
from developmental psychology, including studies with 
autistic children.19,20 Unfortunately, these tests fail to capture 
the dynamic nature and complexities involved in human 
social interaction such as the changes in facial expression, 
voice tone, or gestures that are central to communication 
and convey meaning apart from the content of speech.21 
Additionally, tests that rely heavily on written materi-
als introduce potential confounds associated with reading 
and comprehension ability. Hence, there is a clear need to 
develop and refine new social cognitive assessment measures 
that are appropriate for adults with schizophrenia.
During the Measurement and Treatment Research 
for Improving Cognition in Schizophrenia (MATRICS) 
consensus process,22 experts agreed that tests considered 
for use as endpoints in clinical trials research should be 
evaluated on the following 5 characteristics: (1) discrimi-
nant validity (ie, differences between patients and healthy 
controls), (2) test-retest reliability, (3) utility as a repeated 
measure, (4) tolerability and practicality, and (5) relation-
ship to community functioning. A sixth criterion, sensitiv-
ity to change, was also considered during the MATRICS 
meetings, but it was acknowledged that lack of data did 
not permit this criterion to be adequately assessed. Tests 
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that fail to discriminate between patients and controls are 
unlikely targets for intervention because such tests either 
indicate a relatively preserved area of functioning or insen-
sitivity to group differences.23 A test with poor test-retest 
reliability yields reduced statistical power in clinical trials 
and may undermine the ability to detect significant treat-
ment effects.24 Likewise, tests with high practice effects that 
yield scores close to ceiling (ie, highest possible) would be 
undesirable for the same reason. Regarding tolerability, 
tests that patients do not like to take or are impractical to 
administer and score may lead to early dropout or missing 
data. Finally, because the ultimate goal of new treatments 
for social cognition is to improve the quality of life and 
functioning of individuals, it is hoped that new tests in 
this area would show a relationship to functionally mean-
ingful outcomes. For paradigms drawn from the neurosci-
ence literature, this may present a more vexing issue.
For the Social Cognition and Functioning in 
Schizophrenia (SCAF) project, we selected measures 
from the social neuroscience literature that potentially 
meet the above criteria. This approach seemed like a 
good starting point for finding tasks, given that they had 
been used in neuroscientific investigations and had iden-
tified neural substrates. Such knowledge is important for 
guiding the development of new psychopharmacological 
treatments for social cognitive impairments.25 A potential 
obstacle to adapting tasks from the social neuroscience 
literature, however, is that activation tasks that work per-
fectly well in the scanner with college students may fail 
to satisfy the criteria noted above for use in clinical trials, 
even with careful efforts at adaptation.
The primary aim of this part of the SCAF project 
was to evaluate psychometric properties of 4 such para-
digms to inform possible use in clinical trials that assess 
treatment-related changes in social cognition in schizo-
phrenia. Two of the paradigms assessed perception of 
nonverbal social and action cues, and 2 assessed infer-
ences about others’ mental states. For each measure, we 
examined (1) group differences in performance between 
patients vs healthy controls, (2) test-retest reliability, (3) 
utility as a repeated measure (eg, practice effects, ceil-
ing or floor effects), and (4) tolerability (taking the test 
from the patients’ perspective) and administration time. 
Relationship to functional outcome will be addressed in 
the succeeding article (Olbert et al, this issue).26
Methods
Participants
Schizophrenia participants were recruited from 2 sites: 
(1) University of California, Los Angeles (UCLA)—
outpatient treatment facilities in the Los Angeles 
area and mental health clinics at the VA Greater Los 
Angeles Healthcare System and (2) University of North 
Carolina (UNC)-Chapel Hill Schizophrenia Treatment 
and Evaluation Program and community mental health 
clinics in the Chapel Hill area (total across both sites, n = 
173). Healthy controls were recruited through ads placed 
on the internet (total n = 88).
Selection criteria for schizophrenia participants included 
(1) Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM-IV) diagnosis of schizophrenia 
based on clinical interview, (2) age 18–60  years, (3) able 
to understand spoken English sufficiently to comprehend 
testing procedures, (4) no clinically significant neurologi-
cal disease as determined by medical history (eg, epilepsy), 
(5) no history of serious head injury (ie, loss of conscious-
ness longer than 1 h, no neuropsychological sequelae, no 
cognitive rehabilitation treatment after head injury), (6) 
no evidence of substance or alcohol dependence in the 
past 6 months and no evidence of substance or alcohol 
abuse in past month, (7) no sedatives or benzodiazepines 
within 12 h of testing, (8) no history of mental retarda-
tion or developmental disability based on chart review, 
and (9) clinically stable (ie, no inpatient hospitalizations 
for 3 months prior to enrollment, no changes in antipsy-
chotic medication type in the 4 weeks prior to enrollment). 
Antipsychotic medication type or dose was not controlled 
in the study but was left to the discretion of the patients’ 
treating psychiatrist. All patients were administered the 
Structured Clinical Interview for DSM-IV (SCID-I/P)27 
by trained diagnosticians according to the training qual-
ity assurance procedures used at the respective site. Final 
diagnosis was determined by the site principal investiga-
tor following review of interview data and collateral infor-
mation (eg, medical records, informants). Scale for the 
Assessment of Negative Symptoms (SANS) and Brief  
Psychiatric Rating Scale (BPRS) interviewers were trained 
according to established procedures that included a library 
of videotaped interviews developed by the Treatment Unit 
of the Department of Veterans Affairs VISN 22 Mental 
Illness Research, Education, and Clinical Center. Raters 
were trained to a minimum κ of 0.80.
Selection criteria for healthy controls included (1) no psy-
chiatric history involving schizophrenia spectrum disorder 
(including avoidant, paranoid, schizotypal, or schizoid per-
sonality disorders) according to the SCID-II and no psy-
chotic or recurrent major mood axis I disorder according 
to the SCID-I, (2) no family history of a psychotic disorder 
among first-degree relatives based on participant report, 
and (3) no history of substance or alcohol dependence and 
no current substance use. Criteria concerning age, ability 
to understand English, neurological disease, head trauma, 
and sedative or benzodiazepine use were the same as listed 
for patients above. After providing a complete descrip-
tion of the study to prospective study participants, written 
informed consent was obtained prior to participation.
Procedures
Schizophrenia participants were administered the bat-
tery of social neuroscience paradigms twice (baseline, 
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4-week retest); healthy controls were administered the 
battery once. Severity of symptoms was assessed at both 
testing occasions for patients. The social neuroscience 
paradigms were grouped to form 2 roughly equivalent 
sets. Administration of the 2 sets was counterbalanced 
across subjects to minimize possible confounding effects 
of fatigue or interference from previously administered 
paradigms on task performance. A fifth paradigm assess-
ing situational context effects on facial affect perception 
was dropped based on an interim analysis due to the 
absence of patient vs healthy control group differences. 
The results on this paradigm appear in a separate article.23 
Basic Human Biological Motion. Basic human bio-
logical motion was measured using clips of point-light 
walkers28 administered in 2 blocks of trials (figure 1). 
Difficulty level was manipulated by adjusting the per-
centage of dots moving randomly vs coherently. For each 
trial, clips were presented for 1 s, and participants were 
asked to decide whether the clip resembled human move-
ment or not by pressing a corresponding button. In the 
first block, stimuli were either 100% coherent movement 
or 100% random. Clips depicting movement type were 
presented in random order with 10 trials of each move-
ment type. In the second block, the stimulus set consisted 
of 3 levels of difficulty: 0% coherent, 70% coherent, and 
85% coherent. These clips were also presented in random 
order with 40 trials of each movement type. Adaptation 
of this task for use in clinical trials was accomplished by 
making parameter adjustments that yielded stimuli with 
15% and 30% random motion, which added to difficulty 
level and allowed measurement of signal-to-noise sensi-
tivity. The primary dependent measure was an index of 
sensitivity (d′) per level of difficulty (100% coherent, 85% 
coherent, and 70% coherent).
Emotion in Biological Motion. The ability to perceive 
emotion in biological motion was assessed using the 
point-light walker stimuli developed by Heberlein et al.29 
We adapted this task for clinical trials use by selecting 
a subset of stimuli that captured a range of commonly 
displayed emotions. Thirty point-light walker clips of 
5–10 s in length were presented on a computer screen. 
Participants were asked which of 5 emotional states (fear, 
anger, happiness, sadness, or neutral) best described the 
movement of the walker. The 5 choices for emotional 
state were presented on the computer screen immediately 
after presentation of the clip. The primary dependent 
measure was accuracy measured as percent correct.
Self-Referential Memory. The current paradigm used 
the methods of Kelley et al30 and Macrae et al.31 There 
were 2 task phases (encoding and delayed recognition). 
During the encoding phase, participants completed 3 
types of trials in which they judged (1) whether a trait word 
described themselves (“me” or “not me”; self-referential 
condition), (2) whether the word is a generally desirable 
trait (“desirable” or “not desirable”; other condition), or 
(3) whether it is upper case (“uppercase” or “lowercase”; 
physical condition). Four versions of the task were devel-
oped. For each version, 3 lists of words (total of 78) were 
randomly assigned to the encoding phase (set A) and 3 
lists were used as new words for the recognition phase 
(set B). Word length, number of syllables, valence, and 
frequency ratings were equated across word sets. Half  of 
the trait adjectives were presented in uppercase and half  
in lowercase; half  were positive and half  were negative in 
valence.
Each encoding trial consisted of 2 events: (1) first, a cen-
tral fixation point appeared for 2.5 s, which was followed 
by (2) presentation of a trait adjective appearing below the 
fixation point and an instructional cue word above it for 
2.5 s. The recognition phase took place 20 min later and 
consisted of a yes/no recognition test (3-s trait presenta-
tion, 3-s inter-stimulus interval) for the 78 old words and 
an equal number of unseen new trait words. The dependent 
measure was an index of sensitivity (d′) for recognition of 
words from the self-referential and other conditions.
Empathic Accuracy. The study used 2 versions of an 
empathic accuracy task with roughly half  the subjects 
tested on each version. In the first part of the data col-
lection, we used a variant of a classic empathic accuracy 
paradigm of Levenson and Ruef32 that was developed by 
Zaki and colleagues.33 This was the initial version of the 
task that has been used previously in studies of schizophre-
nia.34,35 Although this version performed well in previous 
studies with schizophrenia, it was limited in a couple of 
ways. First, it was primarily geared for studies with young 
adults (eg, college students), and it had limited diversity 
in terms of age, race, and ethnicity. Thus, it was not well 
suited for older chronic patients with schizophrenia who 
would be typical participants in clinical treatment trials. 
Fig. 1. Example of a point-light walker stimuli.
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In addition, the initial version of the task was not created 
with a type of permission that would enable us to distrib-
ute the task broadly to interested investigators. Hence, 
we developed a new version at UCLA using a new set 
of social targets who gave permissions for broader use, 
including use in clinical trials research. This new version 
also allowed us to capture broader age, racial, and eth-
nic diversity. It was administered to 82 patients and 59 
healthy controls.
In this new UCLA version, participants watched 13 
video clips (7 positive and 6 negative), each lasting for 2.0–
2.5 min. Each clip showed the head and shoulders of 1 of 
6 individuals (targets) while he/she discussed a positive or 
negative autobiographical event. For each clip, participants 
were instructed to press 1 of 2 response keys on a computer 
keyboard to adjust how positive or negative they believed 
the individual was feeling throughout the duration of the 
clip based on a 9-point scale (ranging from 1 = extremely 
negative to 9 = extremely positive). The participant could 
adjust their ratings as frequently as they felt necessary dur-
ing the clip to adjust for changes in emotion. The primary 
dependent measure was the mean correlation across clips 
between the participant’s ratings of the targets’ emotions 
and the targets’ ratings of their own emotions calculated 
in 2-s time epochs throughout the clip. Four clips yielded 
extreme variability in correlation coefficients and were sub-
sequently dropped. For the analyses, we included a short 
6-clip version and a longer 9-clip version. Both versions 
included positive and negative valence clips.
Tolerability and Administration Time
Tolerability refers to the participant’s view of a test (ie, 
how much they liked or did not like taking the test) and 
can be influenced by the length of the test, degree of dif-
ficulty, or monotony. Patients were asked immediately 
after they took each paradigm to point to a number on a 
7-point Likert scale to indicate how unpleasant or pleas-
ant they found it to be (1 = extremely unpleasant; 7 = 
extremely pleasant). We also measured administration 
time for each paradigm to gauge feasibility for use in 
clinical trials.
Symptom Assessments
Raters were trained to reliability following procedures 
used by the respective sites. The expanded BPRS36 was 
used to assess the presence and severity of psychiatric 
symptoms. The dependent measures were factor scores 
for positive and negative symptoms.37 The SANS38 was 
used as an additional measure of negative symptoms. 
The SANS covers 5 areas of negative symptoms based on 
interview and reports of the past month: affective flatten-
ing, alogia, avolition-apathy, anhedonia-asociality, and 
attention. The dependent measures were global scores for 
each subscale, except attention.
Statistical Analyses
Initially, the social neuroscience paradigms were exam-
ined for normality of score distribution by examining 
skewness indices and histograms. None of the measures 
required transformation. For measures yielding d′ indi-
ces, we considered d′ below −0.5 to be invalid (ie, below 
chance). These scores were dropped from the analyses. 
For basic human biological motion, there were a total of 
8 patient outliers over the 2 testing occasions (6 at T1; 
2 at T2), and there were no healthy control outliers; for 
self-referential memory, there were a total of 5 patient 
outliers over the 2 testing occasions (2 at T1; 3 at T2), and 
there was 1 healthy control outlier. Based on examination 
of score distributions for the empathic accuracy task, we 
considered clips yielding individual patient scores of r < 
−.3 to be invalid. These clips were dropped from the final 
9-clip and shorter 6-clip versions used in the analyses. 
Group differences between patients and healthy controls 
were examined by using independent t tests; effect sizes 
were calculated using Cohen’s d. Correlational analyses 
were used to examine test-retest reliability in the schizo-
phrenia sample with the Pearson r correlation coefficient 
used as the index of measurement. Practice effects were 
examined by using paired-samples t tests; within-group 
effect sizes were calculated by dividing the mean differ-
ence score by its SD. Measurement of tolerability and 
administration time was descriptive.
Results
Participants
Across the 2 sites, 173 schizophrenia participants were 
assessed at baseline and 161 at the 4-week retest (93.1% 
retention rate). Table 1 provides the demographic charac-
teristics for patients and healthy controls. The 2 groups 
did not differ in age, parental education, sex, or ethnic-
ity. There was a nonsignificant trend level difference in 
race with the patient group being comprised of a greater 
percentage of black/African Americans relative to con-
trols. As expected, patients had significantly lower edu-
cation and total Wide Range Achievement Test score 
than controls. At baseline assessment, 76.9% were taking a 
second-generation antipsychotic, 10.4% a first- generation 
antipsychotic, 6.4% were taking both, and 1.7% were 
taking other psychoactive medications only; current 
medication type was unknown for 4.6%. Symptom lev-
els were low in this clinically stable sample of outpatients 
and did not differ over the 2 assessments (baseline and 
4-week retest). At the initial assessment, the mean BPRS 
positive symptom factor score was 2.1 (SD = 0.9), and 
the mean BPRS negative symptom factor score was 1.8 
(SD = 0.8). The scores were similar at the 4-week retest 
(mean positive score  =  2.0 [SD = 0.9]; mean negative 
score = 1.9 [SD = 0.9]). Information on the comparison 
of the initial version of the empathic accuracy task with 
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the UCLA version appears in the online supplementary 
data and supplementary table S1.
Site Effects
Site differences were examined in patient performance on 
each of the social neuroscience paradigms. There were 
significant site differences on the 85% coherent move-
ment condition of the basic biological motion task and a 
nonsignificant trend level difference (P = .09) on the self  
condition of the self-referential memory test with higher 
scores at the UCLA site compared to UNC. No other 
comparisons were statistically significant.
Patient vs Healthy Control Group Differences
Patients showed statistically significant differences from 
healthy controls on each measure except the “other” con-
dition of the self-referential memory task (table 2). The 
largest between-group difference was seen on empathic 
accuracy with both the 6- and 9-clip versions of the task 
yielding large effect sizes (Cohen’s d = 0.79). In contrast, 
the self-referential memory task yielded the smallest 
between-group differences with small and small-medium 
effect size differences on the “other” and “self” condi-
tions, respectively.
Test-Retest Reliability
Test-retest reliability data are summarized in table 3. 
Generally a Pearson r = .70 or higher is considered to be 
acceptable/desirable level for clinical trials. Only the 9-clip 
version of the empathic accuracy task met acceptable 
test-retest reliability standards (Pearson r = .72) with the 
6-clip version slightly below (r = .67). These levels com-
pare favorably with those observed on a more standard 
measure of social cognition, the Mayer-Salovey-Caruso 
Emotional Intelligence Test-Managing Emotions branch, 
included in the MATRICS Consensus Cognitive Battery 
(MCCB; intraclass correlation coefficient = 0.73).22 The 
basic biological motion task had poor values on this 
criterion with Pearson rs ranging from .35 to .45 across 
the 3 conditions. The emotion in biological motion and 
self-referential memory tasks yielded higher measures of 
test-retest reliability than basic biological motion, but 
the strength of the correlation coefficients still fell short 
of acceptable standards (emotion in biological motion: 
r = .52; self-referential memory: rs = .59 and .58 for “self” 
and “other” conditions, respectively).
Utility as a Repeated Measure
Tests are considered useful for repeated assessments in 
clinical trials if  they do not have problematic practice 
effects; ie, if  practice effects do exist, they do not raise 
scores to levels approaching ceiling. The strongest mea-
sure in this regard was the empathic accuracy task, which 
showed negligible practice effects from baseline to the 
4-week retest (effect size = 0.0), and there were no scores 
at floor or ceiling. The “other” condition of the self-ref-
erential memory task also behaved well in this regard. 
The “self” condition of this task yielded a nonsignificant 
Table 1. Demographic Characteristics
Patients Controls
n = 173 n = 88
Age 42.8 (12.6) 42.6 (10.1)
Education* 12.8 (1.8) 14.7 (1.9)
Parental education 13.3 (3.1) 13.4 (2.7)
Age of onset (y) 21.7 (7.6)
BPRS positive 2.1 (0.9)
BPRS negative 1.8 (0.8)
SANS affective flattening 1.8 (1.3)
SANS alogia 0.9 (1.2)
SANS avolition-apathy 2.7 (1.1)
SANS anhedonia-asociality 2.3 (1.2)
WRAT* 46.0 (5.9) 50.6 (5.2)
Sex (% men) 71.7 (n = 124) 64.8 (n = 57)
Ethnicity (% Hispanic) 11.6 (n = 20) 11.4 (n = 10)
Race (%)**
 White 51.4 (n = 89) 63.6 (n = 56)
 Black/African American 42.2 (n = 73) 29.5 (n = 26)
 Asian or Pacific Islander 1.7 (n = 3) 4.5 (n = 4)
 More than 1 race 4.6 (n = 8) 2.3 (n = 2)
Note: BPRS, Brief Psychiatric Rating Scale; SANS, Scale for the Assessment of Negative Symptoms; WRAT, Wide Range Achievement Test.
*P < .05, **P < .10.
1206
R. S. Kern et al
trend level difference from baseline to retest, but the 
within-group effect size was small (0.15). The emotion 
in biological motion task yielded a significant differ-
ence between assessment points, but the within-group 
effect size was small for this paradigm as well (0.17). In 
contrast, each condition of the basic biological motion 
task yielded significant within-group differences between 
testing occasions, and the effect sizes ranged from 0.50 
to 0.61. Also, the 100% coherent movement condition 
yielded 11 cases at ceiling at baseline (6.6%), which rose 
to 23 cases at the 4-week retest (14.9%) (table 4).
Tolerability and Administration Time
As presented in table 5, patients considered each measure 
tolerable with little difference noted among tasks. Mean 
schizophrenia participant ratings ranged from 5.0 to 5.4 
across paradigms (scale range: 1 = extremely unpleasant 
to 7 = extremely pleasant). Administration time for the 
majority of measures also appeared acceptable for clini-
cal trials with mean administration times ranging from 
7.5 to 11.7 min. We could not directly measure admin-
istration time for the 6- and 9-clip versions of empathic 
accuracy because administration time was only measured 
for the overinclusive 13-clip original version. We provide 
the cumulative presentation times of the clips, which were 
14.8 and 21.3 min for the 6- and 9-clip versions, respec-
tively. Hence, full administration time including instruc-
tions to patients would be longer, and this paradigm was 
the longest to administer.
Discussion
Social neuroscience is a rich scientific field from which 
new tests can be selected for use as endpoints in clinical 
trials. There are clear advantages to selecting paradigms 
from this field in that the cognitive subprocesses and 
neural substrates associated with task performance are 
already established. However, social neuroscience para-
digms have been largely restricted to use in small sample 
neuroimaging studies (typically with college undergradu-
ates), and their suitability for use in clinical trials requir-
ing repeated assessments over time has been largely 
unexplored.
The current evaluation of social neuroscience paradigms 
coincides with recent efforts conducted by the Cognitive 
Neuroscience Test Reliability and Clinical applications for 
Schizophrenia consortium on a broader set of cognitive 
neuroscience constructs25,39 as well as the Social Cognition 
Psychometric Evaluation study on more standard tests 
of social cognition.40 Results from each of these efforts 
underscore the difficulties in finding psychometrically 





(Cohen’s d)Mean SD Mean SD
Basic biological motion (d′)
 100% Coherent movement 1.72 0.92 2.02 0.86 −2.51 .01 0.34
 85% Coherent movement 1.66 0.88 2.32 0.80 −5.81 .001 0.78
 70% Coherent movement 1.07 0.65 1.53 0.66 −5.30 .001 0.70
Emotion in biological motion  
 (% accuracy)
0.69 0.12 0.77 0.11 −4.97 .001 0.69
Self-referential memory (d′)
 Self 1.30 0.77 1.55 0.67 −2.60 .01 0.35
 Other 1.10 0.72 1.25 0.61 −1.58 .12 0.22
Empathic accuracy (r)
 6 Clips 0.58 0.17 0.69 0.10 −4.38 .001 0.79
  Positive 0.60 0.21 0.71 0.14 −3.36 .001 0.62
  Negative 0.54 0.24 0.66 0.15 −3.30 .001 0.60
 9 Clips 0.59 0.17 0.70 0.10 −4.32 .001 0.79
  Positive 0.63 0.20 0.74 0.13 −3.60 .001 0.65
  Negative 0.54 0.22 0.66 0.14 −3.43 .001 0.65
Table 3. Test-Retest Reliability
Social Neuroscience Paradigm Test Score Used Pearson r
Basic biological motion d′
 100% Coherent movement .35
 85% Coherent movement .45
 70% Coherent movement .45




Empathic accuracy Pearson r
 6 Clips .67
  Positive .50
  Negative .52
 9 Clips .72
  Positive .64
  Negative .74
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strong tests in this area for clinical trials use. Compared to 
the well-established MCCB, the set of social neuroscience 
paradigms evaluated in the current study generally showed 
weaker sensitivity to patient-control group differences and 
weaker test-retest reliability.22,41 It should be noted, how-
ever, that the tests that comprise the MCCB were selected 
with consideration of their psychometric properties from 
over 90 nominated tests.22 These social neuroscience para-
digms were selected because they were ones representa-
tive of social cognitive domains whose neural substrates 
could be reliably identified and because they were relevant 
to social functioning in schizophrenia. Their psychomet-
ric properties were largely unknown. Going forward, it is 
possible that the psychometric characteristics of the cur-
rent paradigms can be enhanced and made comparable to 
tests within the MCCB with further consideration of each 
measure’s methods or item characteristics and modifying 
the test accordingly.
The results from this study showed that only 1 para-
digm, empathic accuracy, currently showed sufficiently 
strong psychometric characteristics to warrant its rec-
ommendation as a candidate for use as a clinical trials 
endpoint. The empathic accuracy paradigm highly dis-
criminated performance between patients and healthy 
controls, showed adequate test-retest reliability, had virtu-
ally no practice effects, and was well tolerated by patients. 
The lone downside of the paradigm was its length.
We also administered a computerized version of  a 
facial affect identification test42 in the current study, 
one typical of  those commonly used in schizophrenia 
research, as an additional benchmark for psychomet-
ric comparison. It discriminated between patients and 
healthy controls (Cohen’s d = 0.59), showed adequate 
test-retest reliability (Pearson r  =  .74), and had sta-
tistically significant, but small, practice effects (effect 
size  =  0.20). The psychometric characteristics of  the 










SizeMean SD Mean SD Mean SD T1 T2
Basic biological motion (d′)
 100% Coherent movement 1.72 0.91 2.24 0.86 0.52 1.01 0/11 0/23 6.35 .001 0.51
 85% Coherent movement 1.65 0.87 2.19 0.80 0.54 0.88 0/0 0/0 7.53 .001 0.61
 70% Coherent movement 1.08 0.65 1.41 0.65 0.34 0.68 0/0 0/0 6.04 .001 0.50
Emotion in biological motion 
 (% accuracy)
0.68 0.12 0.71 0.12 0.02 0.12 0/0 0/0 2.37 .02 0.17
Self-referential memory (d′)
 Self 1.33 0.77 1.21 0.81 −0.11 0.72 0/0 0/0 −1.92 .06 0.15
 Other 1.12 0.73 1.06 0.70 −0.05 0.66 0/0 0/0 −0.99 .32 0.08
Empathic accuracy (r)
 6 Clips 0.57 0.17 0.57 0.20 0.00 0.16 0/0 0/0 −0.08 .94 0.00
  Positive 0.60 0.21 0.60 0.23 0.00 0.22 0/0 0/0 0.13 .90 0.00
  Negative 0.54 0.22 0.56 0.21 0.01 0.21 0/0 0/0 0.59 .56 0.05
 9 Clips 0.58 0.18 0.58 0.18 0.00 0.13 0/0 0/0 −0.24 .81 0.00
  Positive 0.63 0.20 0.62 0.24 −0.01 0.19 0/0 0/0 −0.63 .53 0.05
  Negative 0.56 0.20 0.57 0.19 0.01 0.14 0/0 0/0 0.46 .65 0.07
Table 5. Tolerability and Administration Time
Social Neuroscience Paradigm
Tolerabilitya
Administration Time (min)Participants’ Ratings
Mean SD Mean SD
Basic biological motion 5.2 1.4 7.5 2.2
Emotion in biological motion 5.4 1.4 8.0 1.4
Self-referential memory
 Encoding 5.3 1.3 11.7 2.5
 Recognition 5.0 1.5 9.0 2.9
Empathic accuracyb 5.4 1.4 – –
aRated on a 7-point Likert scale with 1 = extremely unpleasant and 7 = extremely pleasant.
bTotal presentation time for 6-clip version was 14.8 min and for 9-clip version was 21.3 min.
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empathic accuracy task compared favorably with this 
social cognition measure. From a clinical trials per-
spective, one might wonder why consider empathic 
accuracy if  facial affect identification is similar in 
psychometric characteristics plus takes less time to 
administer. However, it is noteworthy that results from 
neuroimaging studies indicate that these 2 tests mea-
sure distinct social cognitive domains with their own 
established social cognitive subprocesses.43–46 For treat-
ment to advance in this area, it is likely that multiple 
social cognition domains will need to be targeted for 
intervention.
The other paradigms examined in this study all had 
limitations for use in clinical trials, at least without 
further adaptation. Self-referential memory and emo-
tion in biological motion showed a mixed pattern of 
strengths and weaknesses. The conditions of  the self-
referential memory paradigm that involved judgments 
about people had relatively low test-retest reliability, 
did not strongly discriminate between patients and 
healthy controls, but yielded small practice effects and 
had good tolerability. Emotion in biological motion 
had weaker test-retest reliability than self-referential 
memory, but better discriminated patients from healthy 
controls and yielded small practice effects and was well 
tolerated. The poorest performing paradigm was basic 
biological motion. It had low test-retest reliability and 
large practice effects, and so would not be recommended 
for clinical trials at this time. One potential influence on 
test-retest reliability and utility as a repeated measure 
is the paradigm’s novelty. In tasks like basic biological 
motion, participants’ performance on the more difficult 
conditions with 15% and 30% random motion com-
monly improves over the first few trials because they 
gain familiarity with the highly novel test stimuli and 
processing demands of  the task. Psychometric limita-
tions affected by task novelty have been noted previ-
ously in other social cognition paradigms (eg, a social 
animation task47). Such paradigms are not optimal 
candidates for use in clinical trials or other investiga-
tions that involve repeat assessments over time without 
further manipulation of  methodological procedures 
to decrease the confound of  novelty effects on perfor-
mance (eg, adding practice trials).
Indeed, these are perilous waters, and careful consid-
eration should be given to addressing the psychometric 
adaptation challenges indicated by these results. The rel-
atively poor reliability of several of the measures raises 
concerns about their use in clinical trials and could reflect 
several factors. For example, it could indicate that some 
social neural subprocesses can be measured more reliably 
than others. Another possibility is that a number of para-
digms drawn from the social neuroscience field are simply 
psychometrically unstable at this point in their develop-
ment. The psychometric characteristics of social neuro-
science paradigms have thus far gone largely unexamined, 
which is not surprising given time and cost considerations 
associated with psychometric studies of imaging para-
digms. While the absence of strong test-retest reliability 
limits confidence in the use of several of these paradigms 
as clinical trials endpoints, the extent to which this is a 
major concern for other types of research is less clear. 
One perspective is that within-subject reliability is essen-
tial to validity for any use of a task in research, including 
activation tasks in neuroimaging. An alternative view is 
that activation tasks could have neural construct valid-
ity (eg, they activate the same neural circuits across labs), 
but poor test-retest reliability due to other factors such as 
practice effects, task novelty, or state-related effects. Such 
a task could be suitable for investigating activation in a 
cross-sectional assessment but unsuitable for repeated 
assessments in clinical trials. This is a topic worthy of 
further evaluation.
On the positive side, this paradigmatic shift in select-
ing new tests for clinical trials has considerable potential 
given the measures’ proximal ties to neural substrates—if 
the psychometric obstacles can be overcome. The chal-
lenge is to refine these paradigms, so that they pass rigor-
ous psychometric evaluation. Such an endeavor appears 
to be more difficult than initially thought. The following 
article in this issue examines the external validity of these 
paradigms.
Supplementary Material
Supplementary material is available at http://schizophre-
niabulletin.oxfordjournals.org.
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